<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909571</url>
  </required_header>
  <id_info>
    <org_study_id>MR-08-04-KOR</org_study_id>
    <nct_id>NCT00909571</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Tacrolimus in Liver Transplantation Patients Treated With Prograf and Modified Release Tacrolimus</brief_title>
  <official_title>A Phase 3 Pilot Study to Describe the Pharmacokinetics of Tacrolimus in Patients Undergoing Primary Liver Donor Liver Transplantation Treated With Prograf Injection and Modified Release Tacrolimus Based Immunosuppressive Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Korea, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tacrolimus pharmacokinetics study in primary living donor liver transplantation patients with
      Tacrolimus based immunosuppressive regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To describe the pharmacokinetics of Tacrolimus when administered as two different doses of
      modified release formulation FK506E(MR4) combined with Prograf injection in patients
      undergoing primary living donor liver transplantation based on the single center (Asan
      Medical Center) standard protocol regimen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of pharmacokinetic parameters</measure>
    <time_frame>Day 6 and Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute rejection</measure>
    <time_frame>within 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to acute rejection</measure>
    <time_frame>within 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of graft survival</measure>
    <time_frame>within 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>1. FK506E high dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2. FK506E low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FK506E (modified release tacrolimus)</intervention_name>
    <description>oral</description>
    <arm_group_label>1. FK506E high dose group</arm_group_label>
    <arm_group_label>2. FK506E low dose group</arm_group_label>
    <other_name>MR4, modified release Tacrolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf (tacrolimus)</intervention_name>
    <description>injection</description>
    <arm_group_label>1. FK506E high dose group</arm_group_label>
    <arm_group_label>2. FK506E low dose group</arm_group_label>
    <other_name>FK506</other_name>
    <other_name>tacrolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients receiving a primary partial liver graft from a living donor

          -  Patients must receive the first dose of Tacrolimus after surgery and are expected to
             be maintained on Tacrolimus throughout the study

        Exclusion Criteria:

          -  Patients receiving a multi-organ transplantation or having previously received an
             organ transplantation

          -  Patients receiving an auxiliary graft or in whom a bio-artificial liver has been used

          -  Patients allergic or intolerant to macrolide antibodies or Tacrolimus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Korea, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2009</study_first_submitted>
  <study_first_submitted_qc>May 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2009</study_first_posted>
  <last_update_submitted>April 15, 2010</last_update_submitted>
  <last_update_submitted_qc>April 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director</name_title>
    <organization>Astellas Pharma, Inc</organization>
  </responsible_party>
  <keyword>FK506E</keyword>
  <keyword>MR4</keyword>
  <keyword>Prograf</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Living Liver Transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

